National Institute of Allergy and Infectious Diseases (NIAID)-funded biomedical research has led to the discovery of novel promising biomedical strategies to treat and prevent HIV and other infectious diseases. Bringing newly discovered treatment and prevention interventions to an Investigational New Drug (IND) stage and into clinical trials is a massive undertaking that, in addition to significant investments, requires a comprehensive understanding of the Food and Drug Administration (FDA) requirements, multidisciplinary expertise, multiple partnerships, and reliable teams
Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
Dec 05 2026
1093 days remaining to event.